

## **Vasculitis Reading List (Part 2 of 2)**

**2008**

Compiled by Purani Palaniswami, MD and Terry Moore, MD

### **GIANT CELL ARTERITIS & POLYMYALGIA RHEUMATICA**

1. [Pipitone N, Salvarani C](#). Improving therapeutic options for patients with giant cell arteritis. *Curr Opin Rheumatol*. 2008 Jan;20(1):17-22. Review.
2. [Cid MC, García-Martínez A, Lozano E, Espígol-Frigolé G, Hernández-Rodríguez J](#). Five clinical conundrums in the management of giant cell arteritis. *Rheum Dis Clin North Am*. 2007 Nov;33(4):819-34, vii. Review.
3. [Bongartz T, Matteson EL](#). Large-vessel involvement in giant cell arteritis. *Curr Opin Rheumatol*. 2006 Jan;18(1):10-7. Review.
4. [Cantini F, Niccoli L, Storri L, Nannini C, Olivieri I, Padula A, et al](#). Are polymyalgia rheumatica and giant cell arteritis the same disease? *Semin Arthritis Rheum*. 2004 Apr;33(5):294-301. Review.
5. [Gonzalez-Gay MA](#). Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. *Semin Arthritis Rheum*. 2004 Apr;33(5):289-93. Review.
6. [Weyand CM, Goronzy JJ](#). Giant-cell arteritis and polymyalgia rheumatica. *Ann Intern Med*. 2003 Sep 16;139(6):505-15. Review.
7. [Salvarani C, Cantini F, Boiardi L, Hunder GG](#). Polymyalgia rheumatica and giant-cell arteritis. *N Engl J Med*. 2002 Jul 25;347(4):261-71. Review.
8. [Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al](#). Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. *Ann Intern Med*. 2007 May 1;146(9):621-30.
  - This is the only RCT reporting the use of a TNF- $\alpha$  inhibitor to treat GCA. In patients with newly diagnosed GCA, infliximab was not superior to placebo with regard to any outcome, including relapse rates and cumulative glucocorticoid dosage.
9. [Lee MS, Smith SD, Galor A, Hoffman GS](#). Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. *Arthritis Rheum*. 2006 Oct;54(10):3306-9.

- This retrospective study suggested that antiplatelet and anticoagulant therapy may decrease the risk of ischemic complications in patients with GCA
10. [Salvarani C, Macchioni P, Manzini C, Paolazzi G, Trotta A, Manganelli P, et al.](#) Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. *Ann Intern Med.* 2007 May 1;146(9):631-9.
  11. [Mahr AD, Jover JA, Spiera RF, Hernández-García C, Fernández-Gutiérrez B, Lavalley MP, et al.](#) Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. *Arthritis Rheum.* 2007 Aug;56(8):2789-97.
    - This is an excellent metaanalysis of the three RCTs on the use of methotrexate as steroid-sparing agent in GCA. It showed that methotrexate is effective in preventing relapses
  12. [Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M, et al.](#) Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. *Arthritis Rheum.* 2004 Apr;50(4):1332-7.
  13. [Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, et al.](#) Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. *Arthritis Rheum.* 2006 Oct;54(10):3310-8.
    - This study provided evidence that induction therapy with high-dose intravenous methylprednisolone for three consecutive days allowed a more rapid tapering of oral glucocorticoid therapy, and resulted in a higher frequency of patients experiencing longstanding remission after glucocorticoid withdrawal

## TAKAYASU'S ARTERITIS

1. [Seo P, Stone JH.](#) Large-vessel vasculitis. *Arthritis Rheum.* 2004 Feb 15;51(1):128-39. Review.
2. [Maksimowicz-McKinnon K, Clark TM, Hoffman GS.](#) Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. *Arthritis Rheum.* 2007 Mar;56(3):1000-1009 Review.
3. [Andrews J, Mason JC.](#) Takayasu's arteritis--recent advances in imaging offer promise. *Rheumatology (Oxford).* 2007 Jan;46(1):6-15. Epub 2006 Oct 13.

4. [Liang P, Hoffman GS](#). Advances in the medical and surgical treatment of Takayasu arteritis. *Curr Opin Rheumatol*. 2005 Jan;17(1):16-24. Review.
5. [Maksimowicz-McKinnon K, Hoffman GS](#). Takayasu arteritis: what is the long-term prognosis? *Rheum Dis Clin North Am*. 2007 Nov;33(4):777-86, vi. Review
6. [Weyand CM, Goronzy JJ](#). Medium- and large-vessel vasculitis. *N Engl J Med*. 2003 Jul 10;349(2):160-9. Review
7. [Vanoli M, Daina E, Salvarani C, Sabbadini MG, Rossi C, Bacchiani G, et al](#). Takayasu's arteritis: A study of 104 Italian patients. *Arthritis Rheum*. 2005 Feb 15;53(1):100-7.
  - This study analyzes a large cohort of patients where Demographic information, clinical history, vascular findings, treatment, risk factors, and comorbidities were analyzed.
8. [Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P](#). Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. *Arthritis Rheum*. 2004 Jul;50(7):2296-304.
  - In this pilot study of relapsing TA, addition of anti-TNF therapy resulted in improvement in 14 of 15 patients and sustained remission in 10 of 15 patients, who were able to discontinue glucocorticoid therapy. Anti-TNF may be a useful adjunct to glucocorticoids in the treatment of Takayasu Arteritis.
9. [Park MC, Lee SW, Park YB, Lee SK, Choi D, Shim WH](#). Post-interventional immunosuppressive treatment and vascular restenosis in Takayasu's arteritis. *Rheumatology (Oxford)*. 2006 May;45(5):600-5. Epub 2005 Dec 13
  - A prospective study showing a lower restenosis rate was observed when the vascular interventions were performed at the stable stage and when post-interventional immunosuppressive treatment was implemented.
10. [Valsakumar AK, Valappil UC, Jorapur V, Garg N, Nityanand S, Sinha N](#). Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. *J Rheumatol*. 2003 Aug;30(8):1793-8.
  - A prospective study to evaluate the role of an immunosuppressive regimen consisting of azathioprine and prednisolone on the clinical, immunological, and angiographic outcome in patients with active Takayasu's arteritis.
11. [Liang P, Tan-Ong M, Hoffman GS](#). Takayasu's arteritis: vascular interventions and outcomes. *J Rheumatol*. 2004 Jan;31(1):102-6.

## **COGAN'S SYNDROME**

1. [Mazlumzadeh M, Matteson EL.](#) Cogan's Syndrome: An Audiovestibular, Ocular and Systemic Autoimmune Disease, *Rheum Dis Clin N Am* 33(2007) 855-874. Review.
2. [Grasland A, Pouchot J, Hachulla E, Blétry O, Papo T, Vinceneux P; Study Group for Cogan's Syndrome.](#) Typical and atypical Cogan's syndrome: 32 cases and review of the literature. *Rheumatology (Oxford)*. 2004 Aug;43(8):1007-15. Epub 2004 May 18. Review.
3. [Matteson EL, Choi HK, Poe DS, Wise C, Lowe VJ, McDonald TJ, et al.](#) Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study. *Arthritis Rheum*. 2005 Jun 15;53(3):337-42.
4. [St Clair EW, McCallum RM.](#) Cogan's syndrome. *Current Opinion in Rheumatology*. 11(1):47-52, January 1999. Review.

## **BEHÇETS SYNDROME**

1. [Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gül A, et al.](#) EULAR recommendations for the management of Behçet's disease: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). *Ann Rheum Dis*. 2008 Jan 31.
2. [Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gül A, et al.](#) Management of Behçet's disease: a systematic literature review for the EULAR evidence based Recommendations for the management of Behçet's disease. *Ann Rheum Dis*. 2008 Apr 17.
3. [Pipitone N, Olivieri I, Cantini F, Triolo G, Salvarani C.](#) New approaches in the treatment of Adamantiades-Behçet's disease. *Curr Opin Rheumatol*. 2006 Jan;18(1):3-9. Review.
4. [Reynolds N.](#) Vasculitis in Behçet's syndrome: evidence-based review. *Curr Opin Rheumatol*. 2008 May;20(3):347-52 Review.
5. [Pipitone N, Olivieri I, Padula A, D'angelo S, Nigro A, Zuccoli G, et al.](#) Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature. *Arthritis Rheum*. 2008 Feb 15;59(2):285-90. Review.

6. [Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al.](#) The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. *Medicine (Baltimore)*. 2003 Jan;82(1):60-76.

## **BUERGERS DISEASE**

1. [Olin JW, Shih A.](#) Thromboangiitis obliterans (Buerger's disease). *Curr Opin Rheumatol*. 2006 Jan;18(1):18-24. Review.

2. [Puéchal X, Fiessinger JN.](#) Thromboangiitis obliterans or Buerger's disease: challenges for the rheumatologist. *Rheumatology (Oxford)*. 2007 Feb;46(2):192-9. Epub 2006 Nov 20. Review.

## **HYPERSENSITIVITY AND URTICARIAL VASCULITIS**

1. [Davis MD, Brewer JD.](#) Urticarial vasculitis and hypocomplementemic urticarial vasculitis syndrome. *Immunol Allergy Clin North Am*. 2004 May;24(2):183-213, vi. Review.

2. [Wisnieski JJ.](#) Urticarial vasculitis. *Curr Opin Rheumatol*. 2000 Jan;12(1):24-31. Review.

## **CRYOGLOBULINEMIC VASCULITIS**

1. [Sansonno D, Carbone A, De Re V, Dammacco F.](#) Hepatitis C virus infection, cryoglobulinaemia, and beyond. *Rheumatology (Oxford)*. 2007 Apr;46(4):572-8. Epub 2007 Feb 22. Review.

2. [Saadoun D, Delluc A, Piette JC, Cacoub P.](#) Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. *Curr Opin Rheumatol*. 2008 Jan;20(1):23-8. Review.

3. [Cacoub P, Delluc A, Saadoun D, Landau DA, Sene D.](#) Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? *Ann Rheum Dis*. 2008 Mar;67(3):283-7. Epub 2007 Jul 20. Review.

4. [Saadoun D, Resche-Rigon M, Sene D, Perard L, Karras A, Cacoub P.](#) Rituximab combined with Peg-Interferon-Ribavirin in refractory HCV-associated cryoglobulinemia vasculitis. *Ann Rheum Dis.* 2008; 67(10):1431-6.
5. [Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P.](#) Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study. *Arthritis Rheum.* 2006 Nov;54(11):3696-706.
6. [Ferri C, Mascia MT.](#) Cryoglobulinemic vasculitis. *Curr Opin Rheumatol.* 2006 Jan;18(1):54-63. Review.

## **HENOCH-SCHÖNLEIN PURPURA**

1. [Dillon MJ.](#) Henoch-Schönlein purpura: recent advances. *Clin Exp Rheumatol.* 2007 Jan-Feb;25(1 Suppl 44):S66-8. Review.
2. [Aalberse J, Dolman K, Ramnath G, Pereira RR, Davin JC.](#) Henoch Schonlein purpura in children: an epidemiological study among Dutch paediatricians on incidence and diagnostic criteria. *Ann Rheum Dis.* 2007 Dec;66(12):1648-50.
3. [Trapani S, Micheli A, Grisolia F, Resti M, Chiappini E, Falcini F, et al.](#) Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. *Semin Arthritis Rheum.* 2005 Dec;35(3):143-53.
4. [Ballinger S.](#) Henoch-Schonlein purpura. *Curr Opin Rheumatol.* 2003 Sep;15(5):591-4. Review.
5. [Ilan Y, Naparstek Y.](#) Henoch Schonlein purpura in children and adults: is it one entity? *Semin Arthritis Rheum.* 2002 Dec;32(3):139-40. Review.
6. [García-Porrúa C, Calviño MC, Llorca J, Couselo JM, González-Gay MA.](#) Henoch-Schönlein purpura in children and adults: clinical differences in a defined population. *Semin Arthritis Rheum.* 2002; 32:149-56.
7. [Coppo R, Andrulli S, Amore A, Gianoglio B, Conti G, Peruzzi L, et al.](#) Predictors of outcome in Henoch-Schönlein nephritis in children and adults. *Am J Kidney Dis.* 2006 Jun;47(6):993-1003.

## VASCULITIS SECONDARY TO CONNECTIVE TISSUE DISEASES

1. [Genta MS, Genta RM, Gabay C](#). Systemic rheumatoid vasculitis: a review. *Semin Arthritis Rheum*. 2006 Oct;36(2):88-98. Review.
2. [Puéchal X, Miceli-Richard C, Mejjad O, Lafforgue P, Marcelli C, Solau-Gervais E, et al](#). Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. *Ann Rheum Dis*. 2008 Jun;67(6):880-4.
3. [Ramos-Casals M, Nardi N, Lagrutta M, Brito-Zerón P, Bové A, Delgado G, et al](#). Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. *Medicine (Baltimore)*. 2006; 85(2):95-104.
4. [Ramos-Casals M, Anaya JM, García-Carrasco M, Rosas J, Bové A, Claver G, et al](#). Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. *Medicine (Baltimore)*. 2004; 83(2):96-106.

## VASCULITIS SECONDARY TO INFECTIONS

1. [Pagnoux C, Cohen P, Guillevin L](#). Vasculitides secondary to infections. *Clin Exp Rheumatol*. 2006 Mar-Apr;24(2 Suppl 41):S71-81. Review.
2. [Guillevin L](#). Virus-induced systemic vasculitides: new therapeutic approaches. *Clin Dev Immunol*. 2004 Sep-Dec;11(3-4):227-31. Review.

## GENERAL REVIEWS OF VASCULITIS

1. [Xu LY, Esparza EM, Anadkat MJ, Crone KG, Brasington RD](#). Cutaneous Manifestations of Vasculitis: A Visual Guide. *Semin Arthritis Rheum*. 2008 Mar 18 Epub ahead of print.
2. [Gonzalez-Gay MA, Garcia-Porrúa C, Salvarani C, Lo Scocco G, Pujol RM](#). Cutaneous vasculitis: a diagnostic approach. *Clin Exp Rheumatol*. 2003 Nov-Dec;21(6 Suppl 32):S85-8. Review.
3. [Fain O, Hamidou M, Cacoub P, Godeau B, Wechsler B, Pariès J, et al](#). Vasculitides associated with malignancies: analysis of sixty patients. *Arthritis Rheum*. 2007 Dec 15;57(8):1473-80.

4. [Stone JH](#). Vasculitis: a collection of pearls and myths. *Rheum Dis Clin North Am*. 2007 Nov;33(4):691-739, v. Review.

5. [Seo P](#). Pregnancy and vasculitis. *Rheum Dis Clin North Am*. 2007 May;33(2):299-317. Review.

6. [Seo P](#), [Stone JH](#). Small-vessel and medium-vessel vasculitis. *Arthritis Rheum*. 2007 Dec 15;57(8):1552-9. Review.